Top Markets
#1 Akedo Akedo +64.36%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +49.34%
#4 Cross Cross +45.41%
#5 Black Phoenix Black Phoenix +34.24%
#6 Velvet Velvet +30.05%
#7 OVERTAKE OVERTAKE +26.38%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +14.75%
#9 Not in Employment, Education, or Training Not in Employment, Education, or Training +14.03%
#10 Palladium Network Palladium Network +12.84%
Coin of the day
Akedo Akedo
Settings
Language
ENGLISH
Currency
USD
Theme
Molecular Pharmacology (USA), Ltd. Molecular Pharmacology (USA), Ltd.

Molecular Pharmacology (USA), Ltd.

MLPH
Rank in Stocks #39109
As a development-stage company, Molecular Pharmacology (USA) Limited (MLPH) is... As a development-stage company, Molecular Pharmacology (USA) Limited (MLPH) is dedicated to the creation and market introduction of solutions for pain and inflammation, with a primary focus on the Australian and United States markets. Through its subsidiary, Molecular Pharmacology Pty. Ltd., it is advancing an analgesic and anti-inflammatory molecule called Tripeptofen, designed to alleviate common daily pain. These products are offered in diverse dosage forms, formulations, and packaging options to suit various needs. MLPH's marketing strategy involves leveraging pharmaceutical distributors and forging collaborative partnerships with companies in the United States and Europe. Additionally, the company maintains an agreement with Dermatology Development Corporation to jointly develop and market a suite of therapeutic, cosmetic, and cosmeceutical items derived from the ThermaLIFE product line and its core active component. Headquartered in Perth, Australia, Molecular Pharmacology (USA) Limited operates as a subsidiary of PharmaNet Group Limited.
Share Price
$0.0322
Last synced: 2026-08-12
Market Cap
$643.71K
Change (1 day)
0.00%
Change (1 year)
544.00%
Country
AU
Trade Molecular Pharmacology (USA), Ltd. (MLPH)

Category

Healthcare
Revenue for Molecular Pharmacology (USA), Ltd. (MLPH)
Revenue in Aug 2026 TTM: 0
According to Molecular Pharmacology (USA), Ltd. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Molecular Pharmacology (USA), Ltd. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE